Drugs / p53 peptide
last change Jan 2013 re-read 2 minutes ago

p53 peptide

Vaccine

Developed for
ovarian neoplasm
Investigated by
National Cancer Institute (NCI)

Trials 1 · a red edge is where a trial was stopped

19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00001827 Jul 1999 → Dec 2007 ovarian neoplasm National Cancer Institute (NCI) Terminated No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as p53 peptide ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001827
Modality Vaccine “vaccination with a p53 peptide” NCT00001827
Route Subcutaneous “injected under the skin” NCT00001827